<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013753</url>
  </required_header>
  <id_info>
    <org_study_id>1222.27</org_study_id>
    <secondary_id>2009-013395-48</secondary_id>
    <nct_id>NCT01013753</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo- and Active-Controlled, Incomplete Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Once Daily Treatment of 4 Doses of BI 1744 CL Inhalation Solution Delivered by the Respimat® in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the efficacy and safety of 4 doses of BI
      1744 CL inhalation solution delivered by the Respimat® inhaler once daily for four weeks in
      patients with asthma in comparison to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response at the End of Each Treatment Period</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Area Under Curve 12-24 h (AUC 12-24h) Response at the End of Each Treatment Period</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 Within 24 Hours Post-dose Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak FEV1 within 24 hours post dose measured following the evening trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h , 3 h, 4 h, 11 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 min, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC Within 24 Hours Post-dose Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC within 24 hours post dose measured following the trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF) Area Under Curve 0-12 Hours (AUC 0-12h) Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF Area Under Curve 12-24 Hours (AUC 12-24h) Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF) Area Under Curve 0-24 Hours (AUC 0-24h) Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak PEF Within 24 Hours Post-dose Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Peak PEF within 24 hours post-dose measured following the evening trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough PEF Response</measure>
    <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
    <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Morning PEF (PEF a.m.)</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>PEF a.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Evening PEF (PEF p.m.)</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>PEF p.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF Daily Variability</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>PEF daily variability was assessed by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). PEF daily variability is the absolute difference between the morning and the evening PEF value divided by the mean of these two values, expressed as a percent. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Morning FEV1 (FEV1 a.m.)</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>FEV1 a.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Evening FEV1 (FEV1 p.m.)</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>FEV1 p.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Rescue Medication During the Whole Day</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>Mean of daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Assessed by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Asthma Symptom Free Days</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>Percentage of asthma-symptom free days after the first 2 weeks of each treatment period was calculated as the number of symptom-free days divided by the number of days on treatment multiplied by 100. A symptom-free day was defined as a day in which no asthma symptoms were recorded, no rescue medication was recorded, activities during the day were not at all limited due to asthma, no shortness of breath during the day was recorded, no wheezing or coughing during the day and no night-time awakenings due to asthma were recorded. Assessed by patients at home using the AM2+ device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Categorized by Highest Number of Night Time Awakenings (Overall)</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Categorized by Worst Asthma Daytime Symptoms (Overall)</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Categorized by Worst Asthma Nighttime Symptoms (Overall)</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Asthma Quality of Life Questionnaire (AQLQ(s)) Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Total score from the Standardised Asthma Quality of Life Questionnaire (AQLQ (s)) at the end of each 4 week treatment period. The AQLQ(s) contains 32 questions, each question has a 7 point scale from 1 (highest intensity) till 7 (no symptoms). Total score was defined as the sum of all items divided by the number of items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Asthma Control Questionnaire (ACQ) Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Control of asthma as assessed by the ACQ at the end of each 4-week treatment period.The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium 1 Hour Pre-dose</measure>
    <time_frame>4 weeks</time_frame>
    <description>Effect on potassium evaluated 1 hour pre-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium 1 Hour Post-dose</measure>
    <time_frame>4 weeks</time_frame>
    <description>Effect on potassium evaluated 1 hour post-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium 3 Hours Post-dose</measure>
    <time_frame>4 weeks</time_frame>
    <description>Effect on potassium evaluated 3 hours post-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</measure>
    <time_frame>4 weeks</time_frame>
    <description>Clinical relevant abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Olodaterol (BI 1744) low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose inhaled orally once daily from the Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol (BI 1744) very low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Very low dose inhaled orally once daily from the Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol (BI 1744) medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium dose inhaled orally once daily from the Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olodaterol (BI 1744) high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose inhaled orally once daily from the Respimat inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol 12 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12mcg inhaled twice daily from the Aerolizer inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI 1744) high</intervention_name>
    <description>Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat</description>
    <arm_group_label>Olodaterol (BI 1744) high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI 1744) medium</intervention_name>
    <description>Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat</description>
    <arm_group_label>Olodaterol (BI 1744) medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI 1744) very low</intervention_name>
    <description>Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat</description>
    <arm_group_label>Olodaterol (BI 1744) very low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol 12 mcg</intervention_name>
    <description>Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups</description>
    <arm_group_label>Formoterol 12 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol (BI 1744) low</intervention_name>
    <description>Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat</description>
    <arm_group_label>Olodaterol (BI 1744) low</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients must sign an informed consent consistent with International Conference on
             Harmonisation-Good Clinical Practice (ICH-GCP) guidelines prior to participation in
             the trial, i.e. prior to any study procedures which includes medication washout and
             restrictions. A separate informed consent is required for pharmacogenomic sampling.

          2. Male or female patients, aged between 18 and 70 years of age, diurnally active

          3. A history of asthma diagnosed by physician at least 3 months prior to Visit 1 at GINA
             treatment steps 3 or 4. The diagnosis of asthma must have been made before the age of
             40.

          4. Pre-bronchodilator FEV1 between 60% predicted and 90% predicted at Visit 1.

          5. Increase in FEV1 greater or equal to 12% and 200 ml 15 minutes after 400mcg salbutamol
             (albuterol) at Visit 1.

          6. Patient must have been taking inhaled corticosteroids (ICS) for at least 12 weeks
             prior to screening, and must have been receiving at a stable dose for at least 6 weeks
             prior to screening either: - a medium to high dose ICS or - a low to high dose ICS in
             combination with Long acting beta agonist (LABA).

          7. All patients must be symptomatic.

        Exclusion criteria:

          1. Patients with a significant disease other than asthma; a significant disease is
             defined as a disease which, in the opinion of the investigator, may (i) put the
             patient at risk because of participation in the study, (ii) influence the results of
             the study, or (iii) cause concern regarding the patient's ability to participate in
             the study

          2. Patients who have been hospitalised for an asthma exacerbation within 3 months or had
             an admission to an intensive care unit for asthma within 3 years of Visit 1

          3. Patients will be excluded when they have: - an aspartate aminotransferase (AST) &gt;80
             IU/L, alanine aminotransferase (ALT) &gt;80 IU/L, bilirubin &gt;1.5 X upper limit of normal
             (ULN) or creatinine &gt;1.5 X ULN - clinically relevant abnormal baseline haematology,
             blood chemistry, or urinalysis

          4. Patients with any of the following conditions: - a diagnosis of thyrotoxicosis

               -  a diagnosis of paroxysmal tachycardia (&gt;100 beats per minute)

               -  a marked baseline prolongation of QT/QTc interval at Visit 1 (e.g., repeated
                  demonstration of a QTc interval &gt;450 ms) as recommended by ICH E14

               -  a history of additional risk factors for Torsade de Pointes (TdP) (e.g., heart
                  failure, hypokalemia, family history of Long QT Syndrome) as recommended by ICH
                  E14.

          5. Patients with any of the following conditions: - a history of myocardial infarction
             within 1 year of screening visit (Visit 1)

               -  a diagnosis of clinically relevant cardiac arrhythmia

               -  a history of cor pulmonale

               -  known active tuberculosis

               -  a malignancy for which patient has undergone resection, radiation therapy or
                  chemotherapy within last five years (patients with treated basal cell carcinoma
                  are allowed)

               -  a history of life-threatening pulmonary obstruction

               -  a history of chronic obstructive pulmonary disease

               -  history of cystic fibrosis

               -  clinically evident bronchiectasis

               -  a history of significant alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1222.27.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schlüsslberg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thalheim bei Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesloch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Proszowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.42101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.42104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.42102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spisska Nova Ves</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.38601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Golnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.38603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoce</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.38605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1222.27.38604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Topolsica</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2009</study_first_submitted>
  <study_first_submitted_qc>November 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2009</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>May 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 5, 2014</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Total</title>
          <description>This was a randomised, double-blind, double dummy, placebo- and active-controlled, 6 treatment, 4 period incomplete crossover trial. 198 patients were assigned randomly to one of 30 treatment sequences, each sequence comprising 4 out of the 6 treatments listed: one of four doses (20 microgram (mcg), 10 mcg, 5 mcg or 2 mcg) of Olodaterol (Olo) once daily (qd) delivered via the Respimat inhaler or Foradil (Form) 12 mcg twice daily (bid) delivered via the Aerolizer inhaler or equivalent placebo. The duration of each treatment period was 4 weeks with no washout periods between treatments.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="198">Entered and treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Placebo</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Olo 2 mcg qd</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Olo 5 mcg qd</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Olo 10 mcg qd</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Olo 20 mcg qd</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Form 12 mcg Bid</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Total</title>
          <description>This was a randomised, double-blind, double dummy, placebo- and active-controlled, 6 treatment, 4 period incomplete crossover trial. 198 patients were assigned randomly to one of 30 treatment sequences, each sequence comprising 4 out of the 6 treatments listed: one of four doses (20 microgram (mcg), 10 mcg, 5 mcg or 2 mcg) of Olodaterol (Olo) once daily (qd) delivered via the Respimat inhaler or Foradil (Form) 12 mcg twice daily (bid) delivered via the Aerolizer inhaler or equivalent placebo. The duration of each treatment period was 4 weeks with no washout periods between treatments.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>Full analysis set (FAS). FAS is defined as all patients in the treated set for whom the baseline (pre-dose) value is available, and who have a value for the primary endpoint for at least one crossover period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-24 Hours (AUC 0-24h) Response at the End of Each Treatment Period</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-24h was calculated from 0-24 hours post-dose using the trapezoidal rule, divided by the observation time (24h) to report in litres.</description>
          <population>Full analysis set (FAS). FAS is defined as all patients in the treated set for whom the baseline (pre-dose) value is available, and who have a value for the primary endpoint for at least one crossover period.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.025"/>
                    <measurement group_id="O2" value="0.135" spread="0.025"/>
                    <measurement group_id="O3" value="0.178" spread="0.025"/>
                    <measurement group_id="O4" value="0.201" spread="0.025"/>
                    <measurement group_id="O5" value="0.225" spread="0.025"/>
                    <measurement group_id="O6" value="0.164" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.140</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.097</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.182</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.140</ci_lower_limit>
            <ci_upper_limit>0.224</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.205</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.163</ci_lower_limit>
            <ci_upper_limit>0.248</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.229</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.186</ci_lower_limit>
            <ci_upper_limit>0.272</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.169</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.126</ci_lower_limit>
            <ci_upper_limit>0.211</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response at the End of Each Treatment Period</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response at the End of Each Treatment Period</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.039" spread="0.026"/>
                    <measurement group_id="O2" value="0.124" spread="0.026"/>
                    <measurement group_id="O3" value="0.173" spread="0.026"/>
                    <measurement group_id="O4" value="0.194" spread="0.026"/>
                    <measurement group_id="O5" value="0.211" spread="0.026"/>
                    <measurement group_id="O6" value="0.145" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.163</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.116</ci_lower_limit>
            <ci_upper_limit>0.211</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.212</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.166</ci_lower_limit>
            <ci_upper_limit>0.259</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.233</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.186</ci_lower_limit>
            <ci_upper_limit>0.280</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.250</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.203</ci_lower_limit>
            <ci_upper_limit>0.298</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.184</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.137</ci_lower_limit>
            <ci_upper_limit>0.231</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Area Under Curve 12-24 h (AUC 12-24h) Response at the End of Each Treatment Period</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under Curve 12-24 h (AUC 12-24h) Response at the End of Each Treatment Period</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FEV1 AUC 12-24h was calculated from 12-24 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.031" spread="0.026"/>
                    <measurement group_id="O2" value="0.147" spread="0.026"/>
                    <measurement group_id="O3" value="0.183" spread="0.025"/>
                    <measurement group_id="O4" value="0.208" spread="0.026"/>
                    <measurement group_id="O5" value="0.238" spread="0.026"/>
                    <measurement group_id="O6" value="0.183" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.115</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.073</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.151</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.110</ci_lower_limit>
            <ci_upper_limit>0.193</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.177</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.135</ci_lower_limit>
            <ci_upper_limit>0.219</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.207</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.164</ci_lower_limit>
            <ci_upper_limit>0.250</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.152</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.110</ci_lower_limit>
            <ci_upper_limit>0.194</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 Within 24 Hours Post-dose Response</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak FEV1 within 24 hours post dose measured following the evening trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Within 24 Hours Post-dose Response</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Peak FEV1 within 24 hours post dose measured following the evening trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.224" spread="0.026"/>
                    <measurement group_id="O2" value="0.326" spread="0.027"/>
                    <measurement group_id="O3" value="0.359" spread="0.026"/>
                    <measurement group_id="O4" value="0.385" spread="0.027"/>
                    <measurement group_id="O5" value="0.404" spread="0.027"/>
                    <measurement group_id="O6" value="0.390" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.102</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.056</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.135</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.090</ci_lower_limit>
            <ci_upper_limit>0.180</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.161</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.116</ci_lower_limit>
            <ci_upper_limit>0.207</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.180</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.134</ci_lower_limit>
            <ci_upper_limit>0.226</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.120</ci_lower_limit>
            <ci_upper_limit>0.211</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response</title>
        <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response</title>
          <description>Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013" spread="0.026"/>
                    <measurement group_id="O2" value="0.116" spread="0.026"/>
                    <measurement group_id="O3" value="0.146" spread="0.026"/>
                    <measurement group_id="O4" value="0.182" spread="0.026"/>
                    <measurement group_id="O5" value="0.211" spread="0.026"/>
                    <measurement group_id="O6" value="0.115" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.058</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.133</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.088</ci_lower_limit>
            <ci_upper_limit>0.177</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.169</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.124</ci_lower_limit>
            <ci_upper_limit>0.214</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.199</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.153</ci_lower_limit>
            <ci_upper_limit>0.244</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.058</ci_lower_limit>
            <ci_upper_limit>0.147</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h , 3 h, 4 h, 11 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) Area Under Curve 0-12 Hours (AUC 0-12h) Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.047" spread="0.029"/>
                    <measurement group_id="O2" value="0.056" spread="0.029"/>
                    <measurement group_id="O3" value="0.109" spread="0.029"/>
                    <measurement group_id="O4" value="0.094" spread="0.029"/>
                    <measurement group_id="O5" value="0.122" spread="0.029"/>
                    <measurement group_id="O6" value="0.055" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.052</ci_lower_limit>
            <ci_upper_limit>0.154</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.106</ci_lower_limit>
            <ci_upper_limit>0.207</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.091</ci_lower_limit>
            <ci_upper_limit>0.192</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.169</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.118</ci_lower_limit>
            <ci_upper_limit>0.221</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.102</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under Curve 12-24 Hours (AUC 12-24h) Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.029"/>
                    <measurement group_id="O2" value="0.055" spread="0.029"/>
                    <measurement group_id="O3" value="0.109" spread="0.028"/>
                    <measurement group_id="O4" value="0.110" spread="0.029"/>
                    <measurement group_id="O5" value="0.139" spread="0.029"/>
                    <measurement group_id="O6" value="0.085" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0107</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.107</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.115</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.069</ci_lower_limit>
            <ci_upper_limit>0.160</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.115</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.069</ci_lower_limit>
            <ci_upper_limit>0.161</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.144</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.191</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.091</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.044</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 min, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under Curve 0-24 Hours (AUC 0-24h) Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. FVC AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.026" spread="0.028"/>
                    <measurement group_id="O2" value="0.056" spread="0.028"/>
                    <measurement group_id="O3" value="0.109" spread="0.028"/>
                    <measurement group_id="O4" value="0.102" spread="0.028"/>
                    <measurement group_id="O5" value="0.131" spread="0.028"/>
                    <measurement group_id="O6" value="0.070" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.036</ci_lower_limit>
            <ci_upper_limit>0.128</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.136</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.090</ci_lower_limit>
            <ci_upper_limit>0.181</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.128</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.083</ci_lower_limit>
            <ci_upper_limit>0.174</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.157</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.111</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC Within 24 Hours Post-dose Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC within 24 hours post dose measured following the trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC Within 24 Hours Post-dose Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Peak FVC within 24 hours post dose measured following the trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.253" spread="0.031"/>
                    <measurement group_id="O2" value="0.300" spread="0.031"/>
                    <measurement group_id="O3" value="0.356" spread="0.031"/>
                    <measurement group_id="O4" value="0.342" spread="0.031"/>
                    <measurement group_id="O5" value="0.380" spread="0.031"/>
                    <measurement group_id="O6" value="0.326" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0952</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.048</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.089</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.034</ci_lower_limit>
            <ci_upper_limit>0.145</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.127</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.071</ci_lower_limit>
            <ci_upper_limit>0.183</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0096</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.073</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.129</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response</title>
        <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response</title>
          <description>Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.022" spread="0.029"/>
                    <measurement group_id="O2" value="0.015" spread="0.029"/>
                    <measurement group_id="O3" value="0.069" spread="0.029"/>
                    <measurement group_id="O4" value="0.088" spread="0.029"/>
                    <measurement group_id="O5" value="0.107" spread="0.029"/>
                    <measurement group_id="O6" value="0.029" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1470</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.013</ci_lower_limit>
            <ci_upper_limit>0.088</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.091</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.042</ci_lower_limit>
            <ci_upper_limit>0.141</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.060</ci_lower_limit>
            <ci_upper_limit>0.160</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.129</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.078</ci_lower_limit>
            <ci_upper_limit>0.179</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0448</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.101</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF) Area Under Curve 0-12 Hours (AUC 0-12h) Response</title>
        <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1 h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF) Area Under Curve 0-12 Hours (AUC 0-12h) Response</title>
          <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-12h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
          <population>FAS</population>
          <units>Liter/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.117" spread="0.076"/>
                    <measurement group_id="O2" value="0.291" spread="0.077"/>
                    <measurement group_id="O3" value="0.449" spread="0.076"/>
                    <measurement group_id="O4" value="0.495" spread="0.077"/>
                    <measurement group_id="O5" value="0.553" spread="0.077"/>
                    <measurement group_id="O6" value="0.471" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.408</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.067</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.277</ci_lower_limit>
            <ci_upper_limit>0.539</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.566</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.066</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.438</ci_lower_limit>
            <ci_upper_limit>0.695</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.612</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.066</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.482</ci_lower_limit>
            <ci_upper_limit>0.743</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.670</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.067</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.539</ci_lower_limit>
            <ci_upper_limit>0.801</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.588</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.066</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.457</ci_lower_limit>
            <ci_upper_limit>0.718</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF Area Under Curve 12-24 Hours (AUC 12-24h) Response</title>
        <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF Area Under Curve 12-24 Hours (AUC 12-24h) Response</title>
          <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 12-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
          <population>FAS</population>
          <units>Liter/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.043" spread="0.075"/>
                    <measurement group_id="O2" value="0.380" spread="0.075"/>
                    <measurement group_id="O3" value="0.528" spread="0.075"/>
                    <measurement group_id="O4" value="0.575" spread="0.075"/>
                    <measurement group_id="O5" value="0.692" spread="0.075"/>
                    <measurement group_id="O6" value="0.594" spread="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.337</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.213</ci_lower_limit>
            <ci_upper_limit>0.461</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.485</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.062</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.363</ci_lower_limit>
            <ci_upper_limit>0.606</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.531</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.408</ci_lower_limit>
            <ci_upper_limit>0.655</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.648</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.524</ci_lower_limit>
            <ci_upper_limit>0.772</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.551</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.063</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.428</ci_lower_limit>
            <ci_upper_limit>0.674</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF) Area Under Curve 0-24 Hours (AUC 0-24h) Response</title>
        <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and -1h, -10 mins, 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF) Area Under Curve 0-24 Hours (AUC 0-24h) Response</title>
          <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Means are adjusted for treatment, period, patient and study baseline. PEF AUC 0-24h was calculated using the trapezoidal rule, divided by the observation time to report in litres/seconds.</description>
          <population>FAS</population>
          <units>Liter/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.038" spread="0.074"/>
                    <measurement group_id="O2" value="0.336" spread="0.074"/>
                    <measurement group_id="O3" value="0.489" spread="0.074"/>
                    <measurement group_id="O4" value="0.534" spread="0.074"/>
                    <measurement group_id="O5" value="0.623" spread="0.074"/>
                    <measurement group_id="O6" value="0.532" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.373</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.061</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.253</ci_lower_limit>
            <ci_upper_limit>0.493</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.527</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.060</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.409</ci_lower_limit>
            <ci_upper_limit>0.645</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.572</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.061</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.453</ci_lower_limit>
            <ci_upper_limit>0.692</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.660</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.061</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.540</ci_lower_limit>
            <ci_upper_limit>0.781</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.570</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.061</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.451</ci_lower_limit>
            <ci_upper_limit>0.689</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak PEF Within 24 Hours Post-dose Response</title>
        <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Peak PEF within 24 hours post-dose measured following the evening trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 30 min, 60 min, 2 h, 3 h, 4 h, 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak PEF Within 24 Hours Post-dose Response</title>
          <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Peak PEF within 24 hours post-dose measured following the evening trial drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.664" spread="0.079"/>
                    <measurement group_id="O2" value="0.966" spread="0.079"/>
                    <measurement group_id="O3" value="1.093" spread="0.078"/>
                    <measurement group_id="O4" value="1.130" spread="0.079"/>
                    <measurement group_id="O5" value="1.198" spread="0.079"/>
                    <measurement group_id="O6" value="1.168" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.302</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.168</ci_lower_limit>
            <ci_upper_limit>0.436</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.429</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.067</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.297</ci_lower_limit>
            <ci_upper_limit>0.561</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.466</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.333</ci_lower_limit>
            <ci_upper_limit>0.599</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.534</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.400</ci_lower_limit>
            <ci_upper_limit>0.669</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.504</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.371</ci_lower_limit>
            <ci_upper_limit>0.637</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough PEF Response</title>
        <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>1 hour (h) prior and 10 minutes (min) prior to first dose (baseline) and 23 h, and 23 h 50 min related to evening dose after 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough PEF Response</title>
          <description>Response was defined as change from baseline. Study baseline PEF was defined as the mean of the available pre-dose PEF values at the randomisation visit. Trough values were defined as the mean of 2 FEV1 values performed at the planned timepoints 23h and 23h 50min related to evening trial-drug inhalation at the end of each 4 week period of randomised treatment. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>Liter/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.031" spread="0.078"/>
                    <measurement group_id="O2" value="0.295" spread="0.078"/>
                    <measurement group_id="O3" value="0.499" spread="0.077"/>
                    <measurement group_id="O4" value="0.515" spread="0.078"/>
                    <measurement group_id="O5" value="0.655" spread="0.078"/>
                    <measurement group_id="O6" value="0.478" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.264</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.070</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.127</ci_lower_limit>
            <ci_upper_limit>0.401</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.468</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.069</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.333</ci_lower_limit>
            <ci_upper_limit>0.602</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.484</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.069</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.348</ci_lower_limit>
            <ci_upper_limit>0.620</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.624</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.070</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.487</ci_lower_limit>
            <ci_upper_limit>0.761</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.447</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.069</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.311</ci_lower_limit>
            <ci_upper_limit>0.583</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Morning PEF (PEF a.m.)</title>
        <description>PEF a.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>2-4 weeks</time_frame>
        <population>FAS including all patients who contributed data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Morning PEF (PEF a.m.)</title>
          <description>PEF a.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS including all patients who contributed data for this endpoint.</population>
          <units>Liter/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.89" spread="4.548"/>
                    <measurement group_id="O2" value="383.90" spread="4.567"/>
                    <measurement group_id="O3" value="390.91" spread="4.519"/>
                    <measurement group_id="O4" value="389.78" spread="4.539"/>
                    <measurement group_id="O5" value="394.82" spread="4.560"/>
                    <measurement group_id="O6" value="385.42" spread="4.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.671</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>14.802</ci_lower_limit>
            <ci_upper_limit>29.223</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>29.022</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.610</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>21.931</ci_lower_limit>
            <ci_upper_limit>36.114</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>27.887</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.631</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>20.755</ci_lower_limit>
            <ci_upper_limit>35.019</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>32.935</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.668</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>25.730</ci_lower_limit>
            <ci_upper_limit>40.139</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23.528</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.644</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>16.371</ci_lower_limit>
            <ci_upper_limit>30.686</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Evening PEF (PEF p.m.)</title>
        <description>PEF p.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>2-4 weeks</time_frame>
        <population>FAS including all patients who contributed data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Evening PEF (PEF p.m.)</title>
          <description>PEF p.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS including all patients who contributed data for this endpoint.</population>
          <units>Liter/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.44" spread="4.398"/>
                    <measurement group_id="O2" value="394.36" spread="4.418"/>
                    <measurement group_id="O3" value="404.28" spread="4.368"/>
                    <measurement group_id="O4" value="403.06" spread="4.389"/>
                    <measurement group_id="O5" value="407.89" spread="4.410"/>
                    <measurement group_id="O6" value="399.88" spread="4.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>14.920</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.640</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.770</ci_lower_limit>
            <ci_upper_limit>22.071</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>24.834</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.580</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>17.801</ci_lower_limit>
            <ci_upper_limit>31.866</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23.613</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.601</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>16.539</ci_lower_limit>
            <ci_upper_limit>30.686</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>28.449</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.637</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>21.305</ci_lower_limit>
            <ci_upper_limit>35.594</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>20.439</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.614</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>13.341</ci_lower_limit>
            <ci_upper_limit>27.538</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF Daily Variability</title>
        <description>PEF daily variability was assessed by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). PEF daily variability is the absolute difference between the morning and the evening PEF value divided by the mean of these two values, expressed as a percent. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>2-4 weeks</time_frame>
        <population>FAS including all patients who contributed data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF Daily Variability</title>
          <description>PEF daily variability was assessed by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). PEF daily variability is the absolute difference between the morning and the evening PEF value divided by the mean of these two values, expressed as a percent. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS including all patients who contributed data for this endpoint.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="122"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.688" spread="0.480"/>
                    <measurement group_id="O2" value="9.694" spread="0.484"/>
                    <measurement group_id="O3" value="9.593" spread="0.475"/>
                    <measurement group_id="O4" value="9.851" spread="0.480"/>
                    <measurement group_id="O5" value="9.899" spread="0.483"/>
                    <measurement group_id="O6" value="10.417" spread="0.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.994</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.507</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.989</ci_lower_limit>
            <ci_upper_limit>-0.999</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.095</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.498</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.073</ci_lower_limit>
            <ci_upper_limit>-1.116</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.836</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.503</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.824</ci_lower_limit>
            <ci_upper_limit>-0.849</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.789</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.506</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.783</ci_lower_limit>
            <ci_upper_limit>-0.795</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0118</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.270</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.503</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.258</ci_lower_limit>
            <ci_upper_limit>-0.283</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Morning FEV1 (FEV1 a.m.)</title>
        <description>FEV1 a.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>2-4 weeks</time_frame>
        <population>FAS including all patients who contributed data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Morning FEV1 (FEV1 a.m.)</title>
          <description>FEV1 a.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS including all patients who contributed data for this endpoint.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.309" spread="0.028"/>
                    <measurement group_id="O2" value="2.402" spread="0.028"/>
                    <measurement group_id="O3" value="2.438" spread="0.028"/>
                    <measurement group_id="O4" value="2.445" spread="0.028"/>
                    <measurement group_id="O5" value="2.479" spread="0.028"/>
                    <measurement group_id="O6" value="2.403" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.093</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.141</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.128</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.081</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.135</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.087</ci_lower_limit>
            <ci_upper_limit>0.183</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.169</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.121</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.093</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.141</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Evening FEV1 (FEV1 p.m.)</title>
        <description>FEV1 p.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>2-4 weeks</time_frame>
        <population>FAS including all patients who contributed data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Evening FEV1 (FEV1 p.m.)</title>
          <description>FEV1 p.m. was measured by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS including all patients who contributed data for this endpoint.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.378" spread="0.027"/>
                    <measurement group_id="O2" value="2.428" spread="0.027"/>
                    <measurement group_id="O3" value="2.460" spread="0.027"/>
                    <measurement group_id="O4" value="2.467" spread="0.027"/>
                    <measurement group_id="O5" value="2.495" spread="0.027"/>
                    <measurement group_id="O6" value="2.457" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0362</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.097</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.081</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.127</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.042</ci_lower_limit>
            <ci_upper_limit>0.135</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.117</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.070</ci_lower_limit>
            <ci_upper_limit>0.164</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.032</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Rescue Medication During the Whole Day</title>
        <description>Mean of daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Assessed by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>2-4 weeks</time_frame>
        <population>FAS including all patients who contributed data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Rescue Medication During the Whole Day</title>
          <description>Mean of daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Assessed by patients at home using the AM2+ device (overall means obtained during each period of randomised treatment excluding the data of the first 2 weeks will be compared). Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS including all patients who contributed data for this endpoint.</population>
          <units>Number of Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.749" spread="0.130"/>
                    <measurement group_id="O2" value="1.222" spread="0.130"/>
                    <measurement group_id="O3" value="1.317" spread="0.128"/>
                    <measurement group_id="O4" value="1.271" spread="0.129"/>
                    <measurement group_id="O5" value="1.092" spread="0.130"/>
                    <measurement group_id="O6" value="1.300" spread="0.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.526</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.124</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.770</ci_lower_limit>
            <ci_upper_limit>-0.282</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.432</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.122</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.671</ci_lower_limit>
            <ci_upper_limit>-0.192</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.478</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.123</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.720</ci_lower_limit>
            <ci_upper_limit>-0.237</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.657</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.124</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.901</ci_lower_limit>
            <ci_upper_limit>-0.413</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.449</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.123</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.691</ci_lower_limit>
            <ci_upper_limit>-0.207</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Asthma Symptom Free Days</title>
        <description>Percentage of asthma-symptom free days after the first 2 weeks of each treatment period was calculated as the number of symptom-free days divided by the number of days on treatment multiplied by 100. A symptom-free day was defined as a day in which no asthma symptoms were recorded, no rescue medication was recorded, activities during the day were not at all limited due to asthma, no shortness of breath during the day was recorded, no wheezing or coughing during the day and no night-time awakenings due to asthma were recorded. Assessed by patients at home using the AM2+ device.</description>
        <time_frame>2-4 weeks</time_frame>
        <population>FAS including all patients who contributed data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Asthma Symptom Free Days</title>
          <description>Percentage of asthma-symptom free days after the first 2 weeks of each treatment period was calculated as the number of symptom-free days divided by the number of days on treatment multiplied by 100. A symptom-free day was defined as a day in which no asthma symptoms were recorded, no rescue medication was recorded, activities during the day were not at all limited due to asthma, no shortness of breath during the day was recorded, no wheezing or coughing during the day and no night-time awakenings due to asthma were recorded. Assessed by patients at home using the AM2+ device.</description>
          <population>FAS including all patients who contributed data for this endpoint.</population>
          <units>Percentage of asthma symptom free days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.502" spread="2.494"/>
                    <measurement group_id="O2" value="26.430" spread="2.973"/>
                    <measurement group_id="O3" value="22.348" spread="2.835"/>
                    <measurement group_id="O4" value="23.624" spread="2.951"/>
                    <measurement group_id="O5" value="21.326" spread="2.803"/>
                    <measurement group_id="O6" value="23.664" spread="2.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Categorized by Highest Number of Night Time Awakenings (Overall)</title>
        <description>Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.</description>
        <time_frame>2-4 weeks</time_frame>
        <population>FAS including all patients who contributed data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Categorized by Highest Number of Night Time Awakenings (Overall)</title>
          <description>Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.</description>
          <population>FAS including all patients who contributed data for this endpoint.</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Did not wake up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="63"/>
                    <measurement group_id="O6" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Woke up once</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Woke up 2-5 times</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Woke up &gt; 5 times</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Was awake all night</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Categorized by Worst Asthma Daytime Symptoms (Overall)</title>
        <description>Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.</description>
        <time_frame>2-4 weeks</time_frame>
        <population>FAS including all patients who contributed data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Categorized by Worst Asthma Daytime Symptoms (Overall)</title>
          <description>Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.</description>
          <population>FAS including all patients who contributed data for this endpoint.</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="54"/>
                    <measurement group_id="O6" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very severe asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Categorized by Worst Asthma Nighttime Symptoms (Overall)</title>
        <description>Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.</description>
        <time_frame>2-4 weeks</time_frame>
        <population>FAS including all patients who contributed data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Categorized by Worst Asthma Nighttime Symptoms (Overall)</title>
          <description>Assessed by patients at home using the AM2+ device after the first 2 weeks of each period of randomised treatment.</description>
          <population>FAS including all patients who contributed data for this endpoint.</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="43"/>
                    <measurement group_id="O6" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very severe asthma symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Asthma Quality of Life Questionnaire (AQLQ(s)) Score</title>
        <description>Total score from the Standardised Asthma Quality of Life Questionnaire (AQLQ (s)) at the end of each 4 week treatment period. The AQLQ(s) contains 32 questions, each question has a 7 point scale from 1 (highest intensity) till 7 (no symptoms). Total score was defined as the sum of all items divided by the number of items.</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS including all patients who contributed data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Asthma Quality of Life Questionnaire (AQLQ(s)) Score</title>
          <description>Total score from the Standardised Asthma Quality of Life Questionnaire (AQLQ (s)) at the end of each 4 week treatment period. The AQLQ(s) contains 32 questions, each question has a 7 point scale from 1 (highest intensity) till 7 (no symptoms). Total score was defined as the sum of all items divided by the number of items.</description>
          <population>FAS including all patients who contributed data for this endpoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="121"/>
                <count group_id="O5" value="118"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.174" spread="0.063"/>
                    <measurement group_id="O2" value="5.463" spread="0.064"/>
                    <measurement group_id="O3" value="5.383" spread="0.063"/>
                    <measurement group_id="O4" value="5.437" spread="0.063"/>
                    <measurement group_id="O5" value="5.491" spread="0.064"/>
                    <measurement group_id="O6" value="5.489" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.289</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.178</ci_lower_limit>
            <ci_upper_limit>0.400</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.209</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.099</ci_lower_limit>
            <ci_upper_limit>0.318</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.262</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.151</ci_lower_limit>
            <ci_upper_limit>0.374</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.317</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.205</ci_lower_limit>
            <ci_upper_limit>0.429</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.315</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.203</ci_lower_limit>
            <ci_upper_limit>0.426</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Asthma Control Questionnaire (ACQ) Score</title>
        <description>Control of asthma as assessed by the ACQ at the end of each 4-week treatment period.The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items.</description>
        <time_frame>4 weeks</time_frame>
        <population>FAS including all patients who contributed data for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Asthma Control Questionnaire (ACQ) Score</title>
          <description>Control of asthma as assessed by the ACQ at the end of each 4-week treatment period.The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items.</description>
          <population>FAS including all patients who contributed data for this endpoint.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="122"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.882" spread="0.058"/>
                    <measurement group_id="O2" value="1.561" spread="0.058"/>
                    <measurement group_id="O3" value="1.589" spread="0.057"/>
                    <measurement group_id="O4" value="1.556" spread="0.058"/>
                    <measurement group_id="O5" value="1.488" spread="0.058"/>
                    <measurement group_id="O6" value="1.536" spread="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.321</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.432</ci_lower_limit>
            <ci_upper_limit>-0.210</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.293</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.403</ci_lower_limit>
            <ci_upper_limit>-0.184</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.326</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.436</ci_lower_limit>
            <ci_upper_limit>-0.215</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.394</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.505</ci_lower_limit>
            <ci_upper_limit>-0.282</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.346</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.457</ci_lower_limit>
            <ci_upper_limit>-0.235</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potassium 1 Hour Pre-dose</title>
        <description>Effect on potassium evaluated 1 hour pre-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.</description>
        <time_frame>4 weeks</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Potassium 1 Hour Pre-dose</title>
          <description>Effect on potassium evaluated 1 hour pre-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.</description>
          <population>Treated set</population>
          <units>mmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="122"/>
                <count group_id="O4" value="117"/>
                <count group_id="O5" value="117"/>
                <count group_id="O6" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.067" lower_limit="4.019" upper_limit="4.114"/>
                    <measurement group_id="O2" value="4.051" lower_limit="4.004" upper_limit="4.099"/>
                    <measurement group_id="O3" value="4.051" lower_limit="4.005" upper_limit="4.097"/>
                    <measurement group_id="O4" value="4.061" lower_limit="4.014" upper_limit="4.109"/>
                    <measurement group_id="O5" value="4.057" lower_limit="4.010" upper_limit="4.105"/>
                    <measurement group_id="O6" value="4.080" lower_limit="4.032" upper_limit="4.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6187</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.996</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.981</ci_lower_limit>
            <ci_upper_limit>1.011</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6022</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.996</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.981</ci_lower_limit>
            <ci_upper_limit>1.011</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8641</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.999</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.984</ci_lower_limit>
            <ci_upper_limit>1.014</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7664</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.998</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.983</ci_lower_limit>
            <ci_upper_limit>1.013</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6757</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.003</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.988</ci_lower_limit>
            <ci_upper_limit>1.018</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potassium 1 Hour Post-dose</title>
        <description>Effect on potassium evaluated 1 hour post-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.</description>
        <time_frame>4 weeks</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Potassium 1 Hour Post-dose</title>
          <description>Effect on potassium evaluated 1 hour post-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.</description>
          <population>Treated set</population>
          <units>mmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="118"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="109"/>
                <count group_id="O6" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.097" lower_limit="4.040" upper_limit="4.155"/>
                    <measurement group_id="O2" value="4.069" lower_limit="4.012" upper_limit="4.126"/>
                    <measurement group_id="O3" value="4.013" lower_limit="3.958" upper_limit="4.069"/>
                    <measurement group_id="O4" value="4.004" lower_limit="3.948" upper_limit="4.060"/>
                    <measurement group_id="O5" value="4.015" lower_limit="3.957" upper_limit="4.073"/>
                    <measurement group_id="O6" value="4.059" lower_limit="4.003" upper_limit="4.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4423</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.993</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.975</ci_lower_limit>
            <ci_upper_limit>1.011</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0218</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.979</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.962</ci_lower_limit>
            <ci_upper_limit>0.997</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0109</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.977</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.960</ci_lower_limit>
            <ci_upper_limit>0.995</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0283</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.980</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.962</ci_lower_limit>
            <ci_upper_limit>0.998</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3085</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.991</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.973</ci_lower_limit>
            <ci_upper_limit>1.009</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potassium 3 Hours Post-dose</title>
        <description>Effect on potassium evaluated 3 hours post-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.</description>
        <time_frame>4 weeks</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Potassium 3 Hours Post-dose</title>
          <description>Effect on potassium evaluated 3 hours post-dose. Analysis is based on the log of the potassium values. For the geometric means, the results were back-transformed to the original scale.</description>
          <population>Treated set</population>
          <units>mmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.029" lower_limit="3.980" upper_limit="4.079"/>
                    <measurement group_id="O2" value="4.026" lower_limit="3.976" upper_limit="4.076"/>
                    <measurement group_id="O3" value="3.997" lower_limit="3.950" upper_limit="4.045"/>
                    <measurement group_id="O4" value="3.979" lower_limit="3.931" upper_limit="4.027"/>
                    <measurement group_id="O5" value="3.992" lower_limit="3.942" upper_limit="4.043"/>
                    <measurement group_id="O6" value="4.007" lower_limit="3.959" upper_limit="4.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9112</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.999</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.984</ci_lower_limit>
            <ci_upper_limit>1.015</ci_upper_limit>
            <estimate_desc>Olo 2 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2955</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.992</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.977</ci_lower_limit>
            <ci_upper_limit>1.007</ci_upper_limit>
            <estimate_desc>Olo 5 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1029</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.987</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.973</ci_lower_limit>
            <ci_upper_limit>1.003</ci_upper_limit>
            <estimate_desc>Olo 10 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2552</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.991</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.975</ci_lower_limit>
            <ci_upper_limit>1.007</ci_upper_limit>
            <estimate_desc>Olo 20 mcg qd minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4803</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a mixed model with treatment, period and study baseline value as fixed effects; and patients as random effect.</method_desc>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.994</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.979</ci_lower_limit>
            <ci_upper_limit>1.010</ci_upper_limit>
            <estimate_desc>Form 12 mcg bid minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</title>
        <description>Clinical relevant abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
        <time_frame>4 weeks</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg qd</title>
            <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg qd</title>
            <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg qd</title>
            <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg qd</title>
            <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O6">
            <title>Form 12 mcg Bid</title>
            <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</title>
          <description>Clinical relevant abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.</description>
          <population>Treated Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="127"/>
                <count group_id="O5" value="124"/>
                <count group_id="O6" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atrioventricular block first degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatine phosphokinase MB increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatine phosphokinase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood pressure increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypothyroidism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Equivalent Placebo (morning and evening) delivered by the matching Inhaler (Respimat or Aerolizer).</description>
        </group>
        <group group_id="E2">
          <title>Olo 2 mcg</title>
          <description>Olodaterol 2 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E3">
          <title>Olo 5 mcg</title>
          <description>Olodaterol 5 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E4">
          <title>Olo 10 mcg</title>
          <description>Olodaterol 10 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E5">
          <title>Olo 20 mcg</title>
          <description>Olodaterol 20 mcg qd (evening, equivalent placebo morning) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E6">
          <title>Form 12 mcg</title>
          <description>Foradil 12 mcg bid (morning and evening) delivered by the Aerolizer Inhaler.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

